Lee's Pharmaceutical Holdings Limited (0950.HK)
HKD 1.36
(2.26%)
HKD 1.36
(2.26%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 70.63 Million HKD | -11.63% |
| 2022 | 79.93 Million HKD | -13.07% |
| 2021 | 91.95 Million HKD | 1125.79% |
| 2020 | 7.5 Million HKD | -43.86% |
| 2019 | 13.36 Million HKD | 1608.95% |
| 2018 | 782 Thousand HKD | 51.55% |
| 2017 | 516 Thousand HKD | -48.45% |
| 2016 | 1 Million HKD | 15.32% |
| 2015 | 868 Thousand HKD | 0.0% |
| 2014 | - HKD | 0.0% |
| 2013 | - HKD | -100.0% |
| 2012 | 319 Thousand HKD | -63.29% |
| 2011 | 869 Thousand HKD | 141.39% |
| 2010 | 360 Thousand HKD | -95.92% |
| 2009 | 8.81 Million HKD | 0.0% |
| 2008 | - HKD | -100.0% |
| 2007 | 450 Thousand HKD | -20.77% |
| 2006 | 568 Thousand HKD | 0.0% |
| 2005 | - HKD | 0.0% |
| 2004 | - HKD | -100.0% |
| 2003 | 3.95 Million HKD | 422.16% |
| 2002 | 758 Thousand HKD | -86.98% |
| 2001 | 5.82 Million HKD | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 FY | 70.63 Million HKD | -11.63% |
| 2023 Q3 | 74.56 Million HKD | -10.97% |
| 2023 Q4 | 70.63 Million HKD | -5.27% |
| 2023 Q1 | 83.76 Million HKD | 4.78% |
| 2023 Q2 | 83.76 Million HKD | 0.0% |
| 2022 Q3 | - HKD | -100.0% |
| 2022 Q4 | 79.93 Million HKD | 0.0% |
| 2022 FY | 79.93 Million HKD | -13.07% |
| 2022 Q1 | - HKD | -100.0% |
| 2022 Q2 | 89.62 Million HKD | 0.0% |
| 2021 FY | 91.95 Million HKD | 1125.79% |
| 2021 Q1 | - HKD | -100.0% |
| 2021 Q4 | 91.95 Million HKD | 0.0% |
| 2021 Q2 | 10.67 Million HKD | 0.0% |
| 2020 Q4 | 7.5 Million HKD | 0.0% |
| 2020 Q1 | - HKD | -100.0% |
| 2020 Q2 | 9.7 Million HKD | 0.0% |
| 2020 FY | 7.5 Million HKD | -43.86% |
| 2019 Q1 | - HKD | -100.0% |
| 2019 FY | 13.36 Million HKD | 1608.95% |
| 2019 Q2 | 4.5 Million HKD | 0.0% |
| 2019 Q4 | 13.36 Million HKD | 0.0% |
| 2018 Q2 | 267 Thousand HKD | 0.0% |
| 2018 FY | 782 Thousand HKD | 51.55% |
| 2018 Q1 | - HKD | -100.0% |
| 2018 Q4 | 782 Thousand HKD | 0.0% |
| 2017 Q1 | - HKD | -100.0% |
| 2017 FY | 516 Thousand HKD | -48.45% |
| 2017 Q4 | 516 Thousand HKD | 0.0% |
| 2017 Q2 | 761 Thousand HKD | 0.0% |
| 2016 FY | 1 Million HKD | 15.32% |
| 2016 Q1 | - HKD | -100.0% |
| 2016 Q2 | 1.27 Million HKD | 0.0% |
| 2016 Q4 | 1 Million HKD | 0.0% |
| 2015 FY | 868 Thousand HKD | 0.0% |
| 2015 Q2 | - HKD | 0.0% |
| 2015 Q4 | 868 Thousand HKD | 0.0% |
| 2015 Q1 | - HKD | 0.0% |
| 2014 Q1 | - HKD | 0.0% |
| 2014 Q4 | - HKD | 0.0% |
| 2014 FY | - HKD | 0.0% |
| 2014 Q2 | - HKD | 0.0% |
| 2013 Q1 | - HKD | -100.0% |
| 2013 FY | - HKD | -100.0% |
| 2013 Q4 | - HKD | 0.0% |
| 2013 Q2 | 22 Thousand HKD | 0.0% |
| 2012 FY | 319 Thousand HKD | -63.29% |
| 2012 Q2 | - HKD | 0.0% |
| 2012 Q4 | 319 Thousand HKD | 0.0% |
| 2011 FY | 869 Thousand HKD | 141.39% |
| 2011 Q2 | 286 Thousand HKD | 0.0% |
| 2011 Q4 | 869 Thousand HKD | 0.0% |
| 2010 Q2 | 7.37 Million HKD | 0.0% |
| 2010 FY | 360 Thousand HKD | -95.92% |
| 2009 FY | 8.81 Million HKD | 0.0% |
| 2008 FY | - HKD | -100.0% |
| 2007 FY | 450 Thousand HKD | -20.77% |
| 2006 FY | 568 Thousand HKD | 0.0% |
| 2005 FY | - HKD | 0.0% |
| 2004 FY | - HKD | -100.0% |
| 2003 FY | 3.95 Million HKD | 422.16% |
| 2002 FY | 758 Thousand HKD | -86.98% |
| 2001 FY | 5.82 Million HKD | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Pak Fah Yeow International Limited | 2.07 Million HKD | -3307.43% |
| Grand Pharmaceutical Group Limited | 990.02 Million HKD | 92.865% |
| Extrawell Pharmaceutical Holdings Limited | 117.12 Million HKD | 39.691% |
| Wai Yuen Tong Medicine Holdings Limited | 276.2 Million HKD | 74.426% |
| Qianhai Health Holdings Limited | - HKD | -Infinity% |
| Essex Bio-Technology Limited | 36.05 Million HKD | -95.902% |
| Tongfang Kontafarma Holdings Limited | 12.8 Million HKD | -451.801% |
| PuraPharm Corporation Limited | 81.09 Million HKD | 12.895% |
| SSY Group Limited | 1.94 Billion HKD | 96.373% |
| JBM (Healthcare) Limited | 43.8 Million HKD | -61.269% |
| Jacobson Pharma Corporation Limited | 592.2 Million HKD | 88.072% |
| China Resources Pharmaceutical Group Limited | 16.61 Billion HKD | 99.575% |